N. Zanaletti

631 total citations
20 papers, 156 citations indexed

About

N. Zanaletti is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, N. Zanaletti has authored 20 papers receiving a total of 156 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in N. Zanaletti's work include Colorectal Cancer Treatments and Studies (11 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). N. Zanaletti is often cited by papers focused on Colorectal Cancer Treatments and Studies (11 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). N. Zanaletti collaborates with scholars based in Italy, Spain and United States. N. Zanaletti's co-authors include Davide Ciardiello, Teresa Troiani, Pasquale Vitale, Erika Martinelli, Stefania Napolitano, Vincenzo De Falco, Emilio Francesco Giunta, Fortunato Ciardiello, Paolo Delrio and Alfonso De Stefano and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Annals of Oncology.

In The Last Decade

N. Zanaletti

20 papers receiving 155 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
N. Zanaletti Italy	8	133	45	37	35	26	20	156
Coralie Cantarel France	6	187 1.4×	66 1.5×	65 1.8×	61 1.7×	31 1.2×	17	220
Qingxia Fan China	7	112 0.8×	37 0.8×	28 0.8×	49 1.4×	25 1.0×	17	156
Ayman Zawadi France	5	101 0.8×	37 0.8×	76 2.1×	28 0.8×	10 0.4×	13	132
Mariaelena Casagrande Italy	8	91 0.7×	37 0.8×	22 0.6×	45 1.3×	8 0.3×	21	123
Matthieu Delaye France	7	171 1.3×	109 2.4×	29 0.8×	61 1.7×	11 0.4×	33	220
Meera Patel United States	6	81 0.6×	29 0.6×	14 0.4×	56 1.6×	20 0.8×	15	127
Massimo Montano Italy	5	145 1.1×	130 2.9×	24 0.6×	54 1.5×	14 0.5×	9	185
Wei‐Chin Chang Taiwan	9	78 0.6×	46 1.0×	17 0.5×	87 2.5×	14 0.5×	19	158
Keigo Chida Japan	6	138 1.0×	52 1.2×	57 1.5×	62 1.8×	17 0.7×	18	194
Rocco Giannicola Italy	8	99 0.7×	22 0.5×	15 0.4×	62 1.8×	29 1.1×	16	196

Countries citing papers authored by N. Zanaletti

Since Specialization

Citations

This map shows the geographic impact of N. Zanaletti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Zanaletti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Zanaletti more than expected).

Fields of papers citing papers by N. Zanaletti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Zanaletti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Zanaletti. The network helps show where N. Zanaletti may publish in the future.

Co-authorship network of co-authors of N. Zanaletti

This figure shows the co-authorship network connecting the top 25 collaborators of N. Zanaletti. A scholar is included among the top collaborators of N. Zanaletti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Zanaletti. N. Zanaletti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Facchini, Sergio, Francesca Collina, Aurora Daniele, et al.. (2023). 1753P Universal DPYD genotyping in patients with gastrointestinal malignancies: Real-world data from a single institution in Italy. Annals of Oncology. 34. S948–S949. 1 indexed citations

Stefano, Alfonso De, N. Zanaletti, Antonino Cassata, et al.. (2023). Heterogeneous disease and intermittent treatment in metastatic colorectal cancer: A case report. Frontiers in Oncology. 13. 1084681–1084681. 1 indexed citations

Tamburini, Emiliano, Davide Tassinari, Alfonso De Stefano, et al.. (2022). Adjuvant chemotherapy after neoadjuvant chemo-radiotherapy and surgery in locally advanced rectal cancer. A systematic review of literature with a meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology. 172. 103627–103627. 19 indexed citations

Vitale, Pasquale, N. Zanaletti, Vincenzo Famiglietti, et al.. (2021). Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. Clinical Colorectal Cancer. 20(3). 227–235. 15 indexed citations

Avallone, Antonio, Alfonso De Stefano, Ugo Pace, et al.. (2020). 491P Neoadjuvant nivolumab in early stage colorectal cancer. Annals of Oncology. 31. S449–S449. 25 indexed citations

Giunta, Emilio Francesco, Giusi Barra, Vincenzo De Falco, et al.. (2020). Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. Scientific Reports. 10(1). 17626–17626. 25 indexed citations

Giunta, Emilio Francesco, Valentina Belli, Salvatore Napolitano, et al.. (2020). 13P Synergistic activity of PARP inhibitor and ATR inhibitor in melanoma cell lines may depend on BRAF-V600 mutation status. Annals of Oncology. 31. S248–S249. 4 indexed citations

Reginelli, Alfonso, Giovanna Vacca, N. Zanaletti, et al.. (2019). Diagnostic value/performance of radiological liver imaging during chemoterapy for gastrointestinal malignancy: a critical review.. Università Politecnica delle Marche (Università Politecnica delle Marche). 90(5-S). 51–61. 4 indexed citations

Falco, Vincenzo De, Pietro Paolo Vitiello, Emilio Francesco Giunta, et al.. (2019). Clinical practice use of liquid biopsy to identify RAS/BRAF mutational status in patients with metastatic colorectal cancer: A single institution experience. Annals of Oncology. 30. iv90–iv90. 1 indexed citations

10.

Viscardi, Giuseppe, N. Zanaletti, Antonello Sica, et al.. (2019). Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature. ESMO Open. 4(5). e000551–e000551. 14 indexed citations

11.

Giunta, Emilio Francesco, Giusi Barra, Vincenzo De Falco, et al.. (2019). IFN-γ/IL-10 ratio as predictive biomarker for response to anti-PD-1 therapy in metastatic melanoma patients. Annals of Oncology. 30. v40–v40. 1 indexed citations

12.

Troiani, Teresa, Erika Martinelli, Davide Ciardiello, et al.. (2019). Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.. Journal of Clinical Oncology. 37(4_suppl). TPS731–TPS731. 8 indexed citations

13.

Falco, Vincenzo De, Stefania Napolitano, Nicola Coppola, et al.. (2019). A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant. Medicine. 98(21). e15759–e15759. 10 indexed citations

14.

Vitiello, Pietro Paolo, Luigi Mele, Claudia Cardone, et al.. (2019). GLPG 1790, a new selective EPHA2 inhibitor, is active in colorectal cancer cell lines belonging to the CMS4/mesenchymal-like subtype. Annals of Oncology. 30. v8–v9. 2 indexed citations

15.

Martinelli, Erika, Teresa Troiani, Claudia Cardone, et al.. (2019). Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon. Annals of Oncology. 30. v251–v251. 5 indexed citations

16.

Vitiello, Pietro Paolo, Claudia Cardone, Davide Ciardiello, et al.. (2018). Combination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four consensus molecular subtypes. Annals of Oncology. 29. viii5–viii5. 2 indexed citations

17.

Falco, Vincenzo De, Emilio Francesco Giunta, Valentina Belli, et al.. (2018). A new natural compound identified through a metabolomic approach has cytotoxic activity against human colorectal cancer cell lines with acquired resistance to cetuximab. Annals of Oncology. 29. viii9–viii9. 1 indexed citations

18.

Cardone, Claudia, Verónica Moreno‐Viedma, Mariel C. Paul, et al.. (2018). AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts). Annals of Oncology. 29. viii30–viii30. 4 indexed citations

19.

Sforza, Vincenzo, Erika Martinelli, Claudia Cardone, et al.. (2017). Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. ESMO Open. 2(4). e000229–e000229. 13 indexed citations

20.

Cardone, Claudia, Mariel C. Paul, Verónica Moreno‐Viedma, et al.. (2017). Eph A2 expression is a predictive biomarker of poorer activity and efficacy of FOLFIRI + cetuximab in RAS WT metastatic colorectal cancer (mCRC) patients (pts) in the CAPRI GOIM trial. Annals of Oncology. 28. v576–v576. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact